Abstract |
Chemoresistance genes have been identified as an impediment to anticancer drug treatment. In particular, P-glycoprotein, the product of the multidrug-resistance (MDR1) gene, plays a major role in clinical treatment failure. Conversely, expression of an MDR1 cDNA in bone marrow of transgenic animals renders hematopoietic cells chemoresistant. Efficient transfer of drug-resistance genes to normal hematopoietic progenitor cells has been achieved with the use of retroviral vectors. In this article we review approaches which use the multidrug-resistance gene to protect bone marrow from myelosuppression following chemotherapy and as a selectable markerin vivo to increase the expression of nonselectable genes which correct hereditary diseases of the hematopoietic system.
|
Authors | T Licht, I Pastan, M M Gottesman, F Herrmann |
Journal | Annals of hematology
(Ann Hematol)
Vol. 72
Issue 4
Pg. 184-93
(Apr 1996)
ISSN: 0939-5555 [Print] Germany |
PMID | 8624371
(Publication Type: Journal Article, Review)
|
Chemical References |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
|
Topics |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
(genetics)
- Genetic Therapy
- Hematologic Diseases
(genetics, therapy)
- Humans
- Neoplasms
(genetics, therapy)
|